Search results
Results from the WOW.Com Content Network
The recommended dose schedule is as follows: Day 1 : Oxaliplatin 85 mg/m 2 intravenous (IV) infusion in 250-500 mL D5W and leucovorin 200 mg/m 2 IV infusion in D5W administered concurrently over 120 minutes in separate bags using a Y-line, followed by fluorouracil (5-FU) 400 mg/m 2 IV bolus given over 2–4 minutes, followed by 5-FU 600 mg/m 2 ...
Fluorouracil (5-FU, 5-fluorouracil), sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. [3] By intravenous injection it is used for treatment of colorectal cancer , oesophageal cancer , stomach cancer , pancreatic cancer , breast cancer , and cervical cancer . [ 3 ]
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer.It is made up of the following drugs: [1] FOL – folinic acid (), a vitamin B derivative with multiple applications, which in this context decreases the cytotoxicity of 5-fluorouracil;
Also, the doses (Day 1: irinotecan 165 mg/m2 IV, plus oxaliplatin 85 mg/m2 IV; Day 1: leucovorin 400 mg/m2; Days 1–3: fluorouracil 1,600 mg/m2/day × 2 days (total 3,200 mg/m2 over 48 hours) continuous infusion starting on day 1; Day 1: bevacizumab 5 mg/kg IV; repeat cycle every 2 weeks) [1] [8] [9] are slightly dissimilar to FOLFIRINOX.
Cyclophosphamide Methotrexate Fluorouracil (CMF) is a commonly used regimen of breast cancer chemotherapy that combines three anti-cancer agents: cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU).
FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer.It is made up of the following four drugs: FOL – folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-fluorouracil (5-FU); [1] [2]
Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU. [1] It was patented in 1967 and approved for medical use in 1972. [2]